Stock Analiz

Atea Pharmaceuticals, Inc. AVIR

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$4.30Market cap $345M
Open the interactive analysis →

Atea Pharmaceuticals, Inc. (AVIR) is a healthcare company listed in the US with a market value of about $345M.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 35% below the current price.

About Atea Pharmaceuticals

Atea Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 1 of the last 8 years in our data. Its share count fell by 2% over three years (buybacks).

Score: 0.6 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield7.4%
Intrinsic value vs. price−35%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)34.5%
ROIC (5-yr avg.)-24.7%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue————$351M$49M——
Net income-$158M-$168M-$136M-$116M$121M-$11M-$14M-$9M
Free cash flow———-$123M-$87M$297M-$13M-$8M
EPS (diluted)$-1.94$-2.00$-1.63$-1.39$1.37$-0.51$-1.39$-0.90
Net margin————34.5%-22.5%——
ROIC-63.0%-34.6%-23.3%-19.7%17.0%-1.6%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $9.00, 109% above the current price; targets range from $8.00 to $10.00; the consensus rating is “Buy”; expected EPS is $-1.68 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Atea Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 35% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Atea Pharmaceuticals pay a dividend?

Not currently.

Is Atea Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Atea Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.